A Randomized, Open Label, Two Period, Single Dose, Two Way Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane in Patients with Locally Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors Sun Pharma Advanced Research Company
- 04 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 04 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 04 Mar 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.